J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal By Reuters
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2025
0mins
Should l Buy JNJ?
Source: Investing.com
J&J Acquires Intra-Cellular Therapies: Johnson & Johnson is set to acquire Intra-Cellular Therapies for $14.6 billion, enhancing its portfolio in neurological treatments and aiming for accelerated growth following the spin-off of its consumer health unit.
Market Reactions and Concerns: The acquisition includes a premium offer for Intra-Cellular's shares, with analysts optimistic about the sales potential of its drug Caplyta; however, concerns regarding potential antitrust scrutiny have been raised due to overlapping products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 234.180
Low
190.00
Averages
218.50
High
240.00
Current: 234.180
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Q1 2026 Earnings Beat Expectations but Stock Declines
- Earnings Beat Expectations: Johnson & Johnson's Q1 2026 earnings report exceeded expectations with approximately $4 billion in revenue from its blood cancer treatment Darzalex, yet investor response was muted, leading to a slight decline in stock price post-release.
- Drug Sales Dynamics: Tremfya, used for treating inflammatory bowel disease and psoriasis, generated $1.6 billion in sales; however, the expiration of Stelara's patent resulted in a significant drop in sales from $1.6 billion in Q1 2025 to $656 million in Q1 2026, highlighting increased competitive pressures.
- Stock Price Analysis: Despite a robust 52% increase in stock price over the past year, recent muted market reactions following the earnings report have led to a pullback, indicating a lack of significant news to drive stock price movements in the short term, warranting caution from investors.
- Long-Term Investment Outlook: Johnson & Johnson has consistently increased its dividend for 64 consecutive years, showcasing stability, and with a promising drug pipeline, despite a higher forward price-to-earnings ratio, it remains attractive by blending stability with upside potential.
See More
Jim Cramer's Trust Adjusts Portfolio with Starbucks and Johnson & Johnson Trades
- Starbucks Reduction: Jim Cramer's Charitable Trust will sell 150 shares of Starbucks at approximately $99.65, realizing about a 19% gain, reflecting confidence in the stock's rebound towards 2026, while reducing its portfolio weight from 3.07% to 2.68%.
- Strong Long-term Strategy: Despite Starbucks trading near its highs for 2026, Cramer remains confident in CEO Brian Niccol's long-term growth strategy, indicating the trust's optimistic outlook on the company's future performance.
- Johnson & Johnson Increase: The trust will purchase 75 shares of Johnson & Johnson at around $234.18, increasing its portfolio weight to 1.40%, demonstrating recognition of the company's strong product pipeline and minimal patent-cliff risk.
- Market Opportunity Capture: Although Johnson & Johnson's stock has slightly declined, Cramer views this as a good opportunity to scale deeper into the investment, especially following the company's strong first-quarter earnings report.
See More
Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
- Acquisition Scale: Eli Lilly announced its agreement to acquire Kelonia Therapeutics for an upfront payment of $3.25 billion, with a total deal value of up to $7 billion, indicating a strategic move in the oncology sector.
- Technological Innovation: Kelonia is developing in vivo CAR-T technology that reprograms T-cells within patients' bodies to attack cancer, potentially simplifying existing cell therapy processes and enhancing treatment efficiency.
- Market Potential: Lilly's oncology head noted that Kelonia's data is 'nothing short of remarkable,' suggesting that this technology could play a significant role in blood cancer treatment, thereby strengthening Lilly's competitive position in the market.
- Future Outlook: The acquisition is expected to close in the second half of 2026, providing Lilly with an opportunity to expand its product line in hematology and further solidify its leadership in the biopharmaceutical industry.
See More
Intuitive Surgical Reports Continued Growth Amid Rising Competition
- Revenue and Earnings Growth: Intuitive Surgical reported $10.1 billion in revenue for 2025, marking a 21% increase, with earnings per share (EPS) of $7.87, up 22.5%, reflecting strong performance and sustained market demand in the medical device sector.
- Surgical System Usage: The da Vinci robotic platform has performed over 20 million surgeries, with the da Vinci Xi system alone used in over 3 million procedures last year, solidifying its leadership in the global multiport robotic surgery market.
- Increased Market Competition: Despite holding a dominant position in robotic surgery, the entry of competitors like Johnson & Johnson and Medtronic, along with Restore Robotics' alternative tools, may pressure its market share, although revenue and procedure volumes continue to rise.
- Technological Innovation and Investment: Intuitive Surgical invested $1.3 billion in R&D last year, and the rollout of the da Vinci 5 system, featuring force feedback technology, is expected to be a major growth catalyst for 2026, further strengthening its market position.
See More
Intuitive Surgical: Leader in Robotic Surgery Market
- Market Dominance: Intuitive Surgical's da Vinci Xi system is the most widely used multiport robotic surgery system globally, utilized in over 3 million surgeries last year; despite a more than 17% drop in stock price this year, its market share remains robust.
- Training Barrier: Most surgeons trained on the da Vinci platform during residency face significant retraining to switch to competitors' systems, making hospitals reluctant to disrupt established workflows in high-stakes surgery, thereby solidifying Intuitive's market position.
- Economic Cycle Advantage: With over 12,100 systems installed globally, 81% of Intuitive's revenue comes from recurring sales of instruments, accessories, and services, making it unlikely for hospitals to replace existing da Vinci systems even if they purchase a competitor's robot due to substantial capital already invested.
- Innovation Drive: The company invested $1.3 billion in R&D last year, with the rollout of the da Vinci 5 expected to be a major catalyst for 2026; its force feedback technology can reduce applied force by up to 43%, improving surgical outcomes and enhancing competitive strength.
See More
Johnson & Johnson's Stock Pullback Amid Strong Momentum
- Earnings Beat: Johnson & Johnson's Q1 2026 earnings surpassed expectations, with notable sales growth from drugs like Darzalex generating $4 billion and Tremfya at $1.6 billion, indicating ongoing progress in its pharmaceutical segment.
- Muted Stock Reaction: Despite positive earnings, the stock fell 0.15%, reflecting investor concerns, particularly after Stelara's patent expiration led to a sales drop from $1.6 billion to $656 million due to increased generic competition.
- Market Outlook: In the short term, Johnson & Johnson's stock may lack significant news catalysts, but its promising drug pipeline and a history of 64 consecutive years of dividend increases suggest long-term stability.
- Valuation Concerns: While the company offers a mix of stability and upside potential, its forward price-to-earnings ratio is higher than in recent quarters, prompting investors to carefully consider the merits of holding shares during this pullback.
See More
Johnson & Johnson Q1 2026 Earnings Beat Expectations but Stock Declines
- Earnings Beat Expectations: Johnson & Johnson's Q1 2026 earnings report exceeded expectations with approximately $4 billion in revenue from its blood cancer treatment Darzalex, yet investor response was muted, leading to a slight decline in stock price post-release.
- Drug Sales Dynamics: Tremfya, used for treating inflammatory bowel disease and psoriasis, generated $1.6 billion in sales; however, the expiration of Stelara's patent resulted in a significant drop in sales from $1.6 billion in Q1 2025 to $656 million in Q1 2026, highlighting increased competitive pressures.
- Stock Price Analysis: Despite a robust 52% increase in stock price over the past year, recent muted market reactions following the earnings report have led to a pullback, indicating a lack of significant news to drive stock price movements in the short term, warranting caution from investors.
- Long-Term Investment Outlook: Johnson & Johnson has consistently increased its dividend for 64 consecutive years, showcasing stability, and with a promising drug pipeline, despite a higher forward price-to-earnings ratio, it remains attractive by blending stability with upside potential.
See More
Jim Cramer's Trust Adjusts Portfolio with Starbucks and Johnson & Johnson Trades
- Starbucks Reduction: Jim Cramer's Charitable Trust will sell 150 shares of Starbucks at approximately $99.65, realizing about a 19% gain, reflecting confidence in the stock's rebound towards 2026, while reducing its portfolio weight from 3.07% to 2.68%.
- Strong Long-term Strategy: Despite Starbucks trading near its highs for 2026, Cramer remains confident in CEO Brian Niccol's long-term growth strategy, indicating the trust's optimistic outlook on the company's future performance.
- Johnson & Johnson Increase: The trust will purchase 75 shares of Johnson & Johnson at around $234.18, increasing its portfolio weight to 1.40%, demonstrating recognition of the company's strong product pipeline and minimal patent-cliff risk.
- Market Opportunity Capture: Although Johnson & Johnson's stock has slightly declined, Cramer views this as a good opportunity to scale deeper into the investment, especially following the company's strong first-quarter earnings report.
See More
Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
- Acquisition Scale: Eli Lilly announced its agreement to acquire Kelonia Therapeutics for an upfront payment of $3.25 billion, with a total deal value of up to $7 billion, indicating a strategic move in the oncology sector.
- Technological Innovation: Kelonia is developing in vivo CAR-T technology that reprograms T-cells within patients' bodies to attack cancer, potentially simplifying existing cell therapy processes and enhancing treatment efficiency.
- Market Potential: Lilly's oncology head noted that Kelonia's data is 'nothing short of remarkable,' suggesting that this technology could play a significant role in blood cancer treatment, thereby strengthening Lilly's competitive position in the market.
- Future Outlook: The acquisition is expected to close in the second half of 2026, providing Lilly with an opportunity to expand its product line in hematology and further solidify its leadership in the biopharmaceutical industry.
See More
Intuitive Surgical Reports Continued Growth Amid Rising Competition
- Revenue and Earnings Growth: Intuitive Surgical reported $10.1 billion in revenue for 2025, marking a 21% increase, with earnings per share (EPS) of $7.87, up 22.5%, reflecting strong performance and sustained market demand in the medical device sector.
- Surgical System Usage: The da Vinci robotic platform has performed over 20 million surgeries, with the da Vinci Xi system alone used in over 3 million procedures last year, solidifying its leadership in the global multiport robotic surgery market.
- Increased Market Competition: Despite holding a dominant position in robotic surgery, the entry of competitors like Johnson & Johnson and Medtronic, along with Restore Robotics' alternative tools, may pressure its market share, although revenue and procedure volumes continue to rise.
- Technological Innovation and Investment: Intuitive Surgical invested $1.3 billion in R&D last year, and the rollout of the da Vinci 5 system, featuring force feedback technology, is expected to be a major growth catalyst for 2026, further strengthening its market position.
See More
Intuitive Surgical: Leader in Robotic Surgery Market
- Market Dominance: Intuitive Surgical's da Vinci Xi system is the most widely used multiport robotic surgery system globally, utilized in over 3 million surgeries last year; despite a more than 17% drop in stock price this year, its market share remains robust.
- Training Barrier: Most surgeons trained on the da Vinci platform during residency face significant retraining to switch to competitors' systems, making hospitals reluctant to disrupt established workflows in high-stakes surgery, thereby solidifying Intuitive's market position.
- Economic Cycle Advantage: With over 12,100 systems installed globally, 81% of Intuitive's revenue comes from recurring sales of instruments, accessories, and services, making it unlikely for hospitals to replace existing da Vinci systems even if they purchase a competitor's robot due to substantial capital already invested.
- Innovation Drive: The company invested $1.3 billion in R&D last year, with the rollout of the da Vinci 5 expected to be a major catalyst for 2026; its force feedback technology can reduce applied force by up to 43%, improving surgical outcomes and enhancing competitive strength.
See More
Johnson & Johnson's Stock Pullback Amid Strong Momentum
- Earnings Beat: Johnson & Johnson's Q1 2026 earnings surpassed expectations, with notable sales growth from drugs like Darzalex generating $4 billion and Tremfya at $1.6 billion, indicating ongoing progress in its pharmaceutical segment.
- Muted Stock Reaction: Despite positive earnings, the stock fell 0.15%, reflecting investor concerns, particularly after Stelara's patent expiration led to a sales drop from $1.6 billion to $656 million due to increased generic competition.
- Market Outlook: In the short term, Johnson & Johnson's stock may lack significant news catalysts, but its promising drug pipeline and a history of 64 consecutive years of dividend increases suggest long-term stability.
- Valuation Concerns: While the company offers a mix of stability and upside potential, its forward price-to-earnings ratio is higher than in recent quarters, prompting investors to carefully consider the merits of holding shares during this pullback.
See More
